Melanoma is the most aggressive form of skin cancer, representing approximately 4% of all cutaneous neoplasms it accounts for up to 80% of deaths. Advanced stages of melanoma involve metastatic processes and are associated with high mortality and morbidity, mainly due to the rapid dissemination and heterogeneous responses to current therapies including immunotherapy. Indeed, immune checkpoints inhibitors (ICIs), either alone or in combination with other therapies are currently used in metastatic melanoma (MM) and linked to an increase in patient survival. Of note, the number of therapeutic regimens for MM patients using ICIs has increased, highlighting a growing need for reliable biomarkers that can both predict and monitor response to ICIs.

中文翻译：

---

黑色素瘤的免疫治疗：我们可以预测循环生物标志物治疗的反应吗？

黑色素瘤是最具侵袭性的皮肤癌，约占所有皮肤肿瘤的 4%，导致死亡人数高达 80%。黑色素瘤的晚期阶段涉及转移过程，并与高死亡率和发病率相关，这主要是由于快速传播和对包括免疫疗法在内的当前疗法的异质反应。事实上，免疫检查点抑制剂（ICIs）无论是单独使用还是与其他疗法联合使用，目前都用于治疗转移性黑色素瘤（MM），并且与患者生存率的提高有关。值得注意的是，使用 ICI 治疗 MM 患者的治疗方案数量有所增加，这凸显了对能够预测和监测 ICI 反应的可靠生物标志物的需求不断增长。